Supplementary data: Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review

These are peer-reviewed supplementary materials for the article 'Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review' published in the Journal of Comparative Effectiveness Research.Table S1: Embase search strategy: combining 6MWT, mortality, hospitalization, and HF.Table S2: Medline search strategy: combining 6MWT, mortality, hospitalization, and HF.Table S3: Gray literature – Conferences searched.Table S4: JBI Risk of bias assessment — randomized controlled trialsTable S5: JBI Risk of bias assessment — cross sectionalTable S6: JBI Risk of bias assessment — cohortTable S7: Study and population characteristicsTable S8: 6MWT and hospitalization: separate outcomesTable S9: 6MWT and mortality: separate outcomesAim: The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are often limited to hospitalization and mortality. Objective: To investigate the relationship between the 6MWT and hospitalization or mortality in CM, including ATTR-CM. Method: A PRISMA-guided systematic literature review was conducted using search terms for CM, 6MWT, hospitalization and mortality. Results: Forty-one studies were identified that reported 6MWT data and hospitalization or mortality data for patients with CM. The data suggest that a greater 6MWT distance is associated with a reduced risk of hospitalization or mortality in CM. Conclusion: The 6MWT is an accepted alternative end point in CM trials, including ATTR-CM.

本数据集为发表于《比较疗效研究杂志》的论文《六分钟步行测试作为心肌病临床试验的临床终点，包括ATTR-CM：系统文献综述》的同行评审补充材料。表S1：Embase搜索策略：结合6MWT、死亡率、住院率和心衰。表S2：Medline搜索策略：结合6MWT、死亡率、住院率和心衰。表S3：灰色文献——搜索过的会议。表S4：JBI偏倚风险评估——随机对照试验。表S5：JBI偏倚风险评估——横断面研究。表S6：JBI偏倚风险评估——队列研究。表S7：研究和人群特征。表S8：6MWT和住院：分离的结局。表S9：6MWT和死亡率：分离的结局。目标：六分钟步行测试（6MWT）是评估心力衰竭（HF）患者功能能力的常用指标。心肌病（CM）临床试验，包括由转甲状腺素蛋白介导的淀粉样变性伴心肌病（ATTR-CM），其首要临床研究终点通常限于住院和死亡率。目的：探究六分钟步行测试（6MWT）与心肌病，包括ATTR-CM中的住院或死亡率之间的关系。方法：采用PRISMA指南进行的系统文献综述，使用CM、6MWT、住院和死亡率的相关搜索词。结果：共确定了41项研究报告了心肌病患者6MWT数据及住院或死亡率数据。数据显示，6MWT步行距离的增加与心肌病中住院或死亡风险的降低相关。结论：6MWT是心肌病临床试验，包括ATTR-CM，中可接受的替代终点。